In Vivo Determination of NAAG in Brain
脑中 NAAG 的体内测定
基本信息
- 批准号:7743831
- 负责人:
- 金额:$ 20.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-12-04 至 2012-11-30
- 项目状态:已结题
- 来源:
- 关键词:AgeAgonistAmyotrophic Lateral SclerosisBipolar DisorderBrainCerebrumCognitionDataDetectionDipeptidesDiseaseFunctional disorderFutureGlutamate Carboxypeptidase IIGlutamatesGrantHumanHuman VolunteersIndividualInvestigationLeadMagnetic Resonance SpectroscopyMapsMeasurementMeasuresMental disordersMethodsN-Methyl-D-Aspartate ReceptorsN-acetylaspartateN-acetylaspartylglutamateNerveNeuraxisNeurobehavioral ManifestationsNeurologicNoisePainPathogenesisPatientsPeptidesPharmacotherapyPilot ProjectsPlayProceduresProtease InhibitorProtonsResearchResolutionRoleSchizophreniaSensory ReceptorsSignal TransductionSpatial DistributionSpecificityStrokeSumSymptomsTechniquesTestingTraumatic Brain InjuryVesiclebasebrain volumeimaging modalityin vivomagnetic fieldmetabotropic glutamate receptor 3novelprefrontal lobepublic health relevancereceptorsexspectroscopic imaging
项目摘要
DESCRIPTION (provided by applicant): N-acetylaspartylglutamate (NAAG) is the most abundant peptide in the human brain. Levels of NAAG have been suggested to be abnormal in patients with disorders such as schizophrenia and amyotrophic lateral sclerosis, amongst others. Until recently, there were no means available for the non-invasive determination of brain NAAG levels. Conventional in vivo proton magnetic resonance spectroscopy has been frequently used to measure the combined resonance of NAAG and N-acetylaspartate (NAA), but it has only limited ability to separately detect the individual components, NAAG and NAA, because of their structural and spectral similarity. We have recently demonstrated that; (a) at field strengths of 3 Tesla, it is possible to use spectral editing techniques to selectively detect NAAG (and NAA) with high specificity, and (b) at very high magnetic field strength (e.g. 7 Tesla for human brain) and with sufficient homogeneity, it is possible to resolve NAA and NAAG directly using proton MR spectroscopic imaging (MRSI). In this pilot R21 application, we propose to further develop and validate methods for NAAG detection and quantitation at both 3 and 7T, and to apply these techniques to a pilot study of patients with schizophrenia at 3T. Regional NAAG levels in 20 patients will be measured and compared to age- and sex-matched normal control subjects. It is expected that this R21 project will provide preliminary data for subsequent, larger studies that will fully elucidate the role of NAAG in schizophrenia. PUBLIC HEALTH RELEVANCE: N-acetylaspartylglutamate (NAAG) is the most abundant peptide in the brain, and is believed to play a central role in the pathogenesis of many cerebral disorders, including schizophrenia, amyotrophic lateral sclerosis, and others. Until recently, there was no direct way of measuring NAAG in the intact human brain. We have developed a new method for measuring NAAG using magnetic resonance spectroscopy (MRS). The purpose of this R21 grant is to extend this technique and map the spatial distribution of NAAG in the brain using MR spectroscopic imaging on high field scanners. The techniques developed will be applied to a pilot study of NAAG levels in patients with schizophrenia. In the long term, this research may lead to a better understanding of schizophrenia and treatment approaches.
描述(由申请人提供):N-乙酰基谷氨酸盐(NAAG)是人脑中含量最丰富的肽。NAAG的水平已经被认为在患有诸如精神分裂症和肌萎缩侧索硬化症等疾病的患者中是异常的。直到最近,还没有可用于非侵入性测定脑NAAG水平的方法。传统的在体质子磁共振波谱已被频繁地用于测量NAAG和N-乙酰天冬氨酸(NAA)的组合共振,但它只有有限的能力,分别检测的单个组件,NAAG和NAA,因为它们的结构和光谱的相似性。我们最近已经证明:(a)在3特斯拉的磁场强度下,可以使用光谱编辑技术以高特异性选择性地检测NAAG(和NAA),以及(B)在非常高的磁场强度(例如,人脑为7特斯拉)和足够的均匀性下,可以使用质子MR光谱成像(MRSI)直接解析NAA和NAAG。在这个试点R21的应用程序中,我们建议进一步开发和验证NAAG检测和定量的方法在3和7 T,并将这些技术应用到一个试点研究的精神分裂症患者在3 T。将测量20名患者的局部NAAG水平,并与年龄和性别匹配的正常对照受试者进行比较。预计R21项目将为后续更大规模的研究提供初步数据,以充分阐明NAAG在精神分裂症中的作用。公共卫生相关性:N-乙酰基谷氨酸(NAAG)是脑中最丰富的肽,并且被认为在许多脑疾病的发病机制中起中心作用,包括精神分裂症、肌萎缩侧索硬化症等。直到最近,还没有直接的方法来测量完整人脑中的NAAG。我们已经开发了一种新的方法来测量NAAG使用磁共振波谱(MRS)。这项R21资助的目的是扩展这项技术,并使用高场扫描仪上的MR光谱成像绘制NAAG在大脑中的空间分布。所开发的技术将应用于精神分裂症患者NAAG水平的试点研究。从长远来看,这项研究可能会导致更好地了解精神分裂症和治疗方法。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
GABA predicts inhibition of frequency-specific oscillations in schizophrenia.
GABA预测了精神分裂症中频率特异性振荡的抑制。
- DOI:10.1176/appi.neuropsych.11120368
- 发表时间:2013
- 期刊:
- 影响因子:0
- 作者:Rowland LM;Edden RA;Kontson K;Zhu H;Barker PB;Hong LE
- 通讯作者:Hong LE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER B BARKER其他文献
PETER B BARKER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER B BARKER', 18)}}的其他基金
Quantitative MRSI to predict early response to SAHA therapy in new GBM management
定量 MRSI 可预测新 GBM 治疗中 SAHA 治疗的早期反应
- 批准号:
8890122 - 财政年份:2013
- 资助金额:
$ 20.03万 - 项目类别:
Quantitative MRSI to predict early response to SAHA therapy in new GBM management
定量 MRSI 可预测新 GBM 治疗中 SAHA 治疗的早期反应
- 批准号:
8416461 - 财政年份:2013
- 资助金额:
$ 20.03万 - 项目类别:
Quantitative MRSI to predict early response to SAHA therapy in new GBM management
定量 MRSI 可预测新 GBM 治疗中 SAHA 治疗的早期反应
- 批准号:
8715738 - 财政年份:2013
- 资助金额:
$ 20.03万 - 项目类别:
Quantitative MRSI to predict early response to SAHA therapy in new GBM management
定量 MRSI 可预测新 GBM 治疗中 SAHA 治疗的早期反应
- 批准号:
9308872 - 财政年份:2013
- 资助金额:
$ 20.03万 - 项目类别:
Neurotransmitters in Schizophrenia using high-field MR Spectroscopy
使用高场磁共振波谱研究精神分裂症中的神经递质
- 批准号:
8492164 - 财政年份:2012
- 资助金额:
$ 20.03万 - 项目类别:
Neurotransmitters in Schizophrenia using high-field MR Spectroscopy
使用高场磁共振波谱研究精神分裂症中的神经递质
- 批准号:
8627212 - 财政年份:2012
- 资助金额:
$ 20.03万 - 项目类别:
Neurotransmitters in Schizophrenia using high-field MR Spectroscopy
使用高场磁共振波谱研究精神分裂症中的神经递质
- 批准号:
8391934 - 财政年份:2012
- 资助金额:
$ 20.03万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 20.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 20.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别: